NCT03418285 is a clinical trial in Myocardial Infarction, sponsored by Yokohama City University Medical Center.

Who is sponsoring NCT03418285?

NCT03418285 is sponsored by Yokohama City University Medical Center.

What condition does NCT03418285 study?

NCT03418285 studies Myocardial Infarction.

Is NCT03418285 still recruiting?

NCT03418285 is currently completed. Last updated 5 February 2018.

Last reviewed 2018-02-05 · How we verify

NCT03418285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trimethylamine N-oxide in Myocardial Infarction

Completed Last updated 5 February 2018

What this trial tests

trial in Myocardial Infarction in 112 participants. Completed in 1 January 2018.

Timeline

1 January 2007

Primary endpoint
1 January 2018

1 January 2018

Quick facts

Lead sponsor	Yokohama City University Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	112
Start date	1 January 2007
Primary completion	1 January 2018
Estimated completion	1 January 2018

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Yokohama City University Medical Center

Who can join

Adults 20 to 100, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trimethylamine-N-oxide (TMAO) is produced from the metabolism of gut microbiota and is reportedly pro-atherogenic and associated with cardiovascular events. The purpose of this study is to investigate the sequential change in TMAO levels by current optimal secondary prevention therapies in patients with ST-elevation acute myocardial infarction (STEMI) and the clinical impact of TMAO levels on the progression of atherosclerosis and subsequent cardiovascular events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI.
Matsuzawa Y, Nakahashi H, Konishi M, Sato R, et al · · 2019 · cited 42× · PMID 31406181 · DOI 10.1038/s41598-019-48246-6

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03418285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yokohama City University Medical Center
Last refreshed: 5 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03418285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing